期刊文献+

PRPS2在宫颈癌组织中的表达水平及抑癌机制分析

Expression level of PRPS2 in cervical cancer and cancer suppression mechanism
下载PDF
导出
摘要 目的 分析磷酸核糖焦磷酸合成酶2(PRPS2)在宫颈癌中的表达情况及抑癌作用。方法 上海市崇明区第三人民医院采集的66例宫颈癌患者癌组织及20份癌旁组织(距癌组织> 1 cm)标本,免疫组化法检测宫颈癌组织及癌旁组织PRPS2表达;并选择宫颈癌He La细胞,脂质体转染PRPS2小干扰序列(He La-PRPS2组),并设计He La-NC对照组(转染无关siRNA序列)。蛋白印迹法(WB)测定PRPS2干扰效率,四甲基偶氮唑盐法(MTT)检测细胞增殖情况,Transwell侵袭实验检测细胞侵袭能力,流式细胞仪测定细胞凋亡情况,总结PRPS2抑癌机制。结果 ①宫颈癌癌组织PRPS2阳性率为75. 76%,高于癌旁组织25. 00%(P <0. 05);②He La-PRPS2组PRPS2蛋白表达量低于He La-NC对照组(P <0. 05);③He La-NC对照组干扰不同时间增殖活性均高于He La-PRPS2组(P <0. 05);④He La-NC对照组穿膜细胞比率高于He La-PRPS2组(P <0. 05);⑤转染后He La-NC对照组G0/G1期细胞比率高于He La-PRPS2组(P <0. 05),G2/M期细胞比率低于He La-PRPS2组(P <0. 05),细胞凋亡率低于He La-PRPS2组(P <0. 05)。结论宫颈癌癌组织PRPS2呈过表达,沉默宫颈癌细胞株He La PRPS2表达后细胞增殖、侵袭能力降低,细胞凋亡率增加,推测沉默PRPS2表达存在抑癌效应。 Objective To analyze expression of Phosphoribosyl-Pyrophosphate Synthetase 2(PRPS2)in cervical cancer and its anti-cancer effect.Methods The specimens of cancer tissues from 66 cervical cancer patients and 20 para-cancerous tissues(above 1 cm away from cancer)were collected.The expression of PRPS2 in cervical cancer tissues and para-cancerous tissues was detected by immunohistochemistry.The cervical cancer HeLa cells were enrolled.The liposomes were transfected with PRPS2 small interference sequence(HeLa-PRPS2 group).HeLa-NC control group was set up.Western blotting method(WB)was applied to measure interference efficiency of PRPS2.Methyl thiazolyl tetrazolium(MTT)assay was applied to detect cell proliferation.Transwell invasion test was applied to detect cell invasive ability.The apoptosis was detected by flow cytometry.The cancer suppression mechanism of PRPS2 was summarized.Results①The positive rate of PRPS2 in cervical cancer para-cancerous tissues was lower than that in cancer tissues(25.00%vs.75.76%)(P<0.05).②The expression quantity of PRPS2 protein in HeLa-PRPS2 group was lower than that in HeLa-NC control group(P<0.05).③The proliferation activity in HeLa-NC control group was higher than that in HeLa-PRPS2 group at different time points after interference(P<0.05).④The ratio of transmembrane cells in HeLa-NC control group was higher than that in HeLa-PRPS2 group(P<0.05).⑤After transfections,proportion of cells in G0/G1 phase of HeLa-NC control group was higher than that of HeLa-PRPS2 group(P<0.05),while proportion of cells in G2/M phase was lower than that of HeLa-PRPS2 group(P<0.05),and apoptosis rate was lower than that of HeLa-PRPS2 group(P<0.05).Conclusion PRPS2 in cervical cancer tissues is over-expressed.After silencing expression of cervical cancer cell line HeLa PRPS2,cell proliferation and invasion ability are decreased,while apoptosis rate is increased.It is speculated that silencing PRPS2 expression is of cancer suppression effect.
作者 袁佐杰 沈军 邹斌 YUAN Zuo-jie;SHEN Jun;ZOU Bin(Department of Clinical Laboratory,Shanghai Chongming District Third People's Hospital,Shanghai 202153,China;Medical Inspection Center,Shanghai General Hospital,Shanghai 200080,China.)
出处 《临床和实验医学杂志》 2020年第8期829-833,共5页 Journal of Clinical and Experimental Medicine
基金 上海市科学技术基金委员会资助项目(编号:15411952300)。
关键词 宫颈癌 小干扰技术 磷酸核糖焦磷酸合成酶 2 增殖 侵袭 凋亡 Cervical cancer Small interference technique Phosphoribose phosphate synthase 2 Proliferation Invasion Apoptosis
  • 相关文献

参考文献6

二级参考文献34

  • 1王华,陈亚宝,叶丽华,叶军,袁冬兰.应用支链DNA技术检测人乳头瘤病毒E6/E7mRNA在宫颈疾病筛查中的价值[J].中华临床医师杂志(电子版),2011,5(15):4362-4366. 被引量:29
  • 2Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update[J]. J Clin Oncol, 2011, 29(5):551-565.
  • 3Henze G, v Stackelberg A, Eckert C. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia[J]. Kiln Padiatr, 2013,225(Suppl 1):$73-78.
  • 4Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial[J]. Lancet, 2010, 376(9757):2009-201 7.
  • 5Li B, Li H, Bai Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL[J]. Nat Med, 201 5, 21 (6):563-571.
  • 6Innocenti F, Danesi R, Di Paolo A, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate[j]. Cancer Chemother Pharmacol, 1996, 37(5):409-414.
  • 7Giverhaug T, Loennechen T, Aarbakke J. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX)LI]. Gen Pharmacol, 1999, 33(4):341-346.
  • 8Balls FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine[J]. C/in Pharmacol ?-her, 1987, 41 (4):384-387.
  • 9BokkerinkJP, Bakker MA, Hulscher TW, et al. Sequence-, time- and dose- dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts[j]. Biochem Pharmacol, 1986, 35(20):3549-3555.
  • 10Bokkerink JP, Damen FJ, Hulscher MW, et al. Biochemical evidence for synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia[J]. Haematol Blood Transfus, 1990, 33:110-117.

共引文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部